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There is growing evidence that viral infections 
contribute to the induction or progression of 
metabolic diseases, potentially through infl am-
mation and other unknown mechanisms. Viral 
infections have been linked to defects in cho-
lesterol metabolism (1), such as atherosclerosis, 
and liver metabolism of drugs, as in Reye’s syn-
drome (2), as well as bone metabolism defects, 
skin eruptions, and diabetes (3–6). There is also 
evidence that maternal viral infections can lead 
to the maternal immune system aff ecting 
embryonic development, as seen in TORCH 
infections (7).
A common mechanism in the develop-
ment of metabolic disorders is the alteration of 
gene expression controlled by nuclear hormone 
receptors. Members of this family function as 
transcriptional regulators of metabolic path-
ways in multiple cell types. Retinoic X recep-
tors (RXRs) play a uniquely important role 
in metabolism because of their ability to form 
heterodimers with many diff erent nuclear 
receptors, including peroxisome proliferator–
activated receptors (PPARs) liver X receptor 
(LXR), farnesoid X receptor (FXR), vitamin 
D receptor (VDR), thyroid hormone receptor, 
pregnane X receptor (PXR), and constitutive 
androstane receptor (8–17). Thus, any signal 
that alters RXR function or expression has 
the potential to aff ect multiple diff erent met-
abolic programs. A range of intermediates or 
end products of metabolic pathways, including 
bile acids, fatty acids, oxysterols, and steroids, 
have been shown to regulate gene expression 
through direct binding to RXR hetrodimeric 
receptors (11–13, 18–26). Two diff erent RXR 
heterodimer partners, constitutive androstane 
receptor and PXR, are activated by xenobi-
otics and participate in hepatic detoxifi cation 
pathways. Studies using knockout mice have 
confi rmed that these proteins are essential for 
proper steroid, drug, and xenobiotic metabo-
lism (18, 23–25, 27). Challenging these mice 
with xenobiotics or toxic bile acids leads to fatty 
degeneration, acute liver failure, and death.
Previous work has pointed to the existence 
of cross talk between nuclear receptor signal-
ing and the innate immune response. Induc-
tion of acute phase response by treating mice 
with LPS has been associated with the down-
regulation of certain nuclear receptors in the liver, 
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including RXR (28–30). Recently, the induction of an an-
tiviral immune response in macrophages has been shown to 
inhibit LXR/RXR function and cholesterol effl  ux, suggest-
ing a possible mechanism for viral-induced foam cell forma-
tion in atherosclerosis (31). Although the precise mechanisms 
whereby bacterial or viral infections inhibit nuclear receptor 
function are unknown, experiments on LXR have impli-
cated IFN regulatory factor 3 (IRF3) (31).
IRF3 is a transcription factor shared by both LPS signal-
ing and the antiviral immune response. Upon viral infection 
or stimulation with Toll-like receptor (TLR) agonists such 
as polyinosine-polycytidylic acid (polyI:C) or LPS, IRF3 is 
phosphorylated by serine/threonine kinases such as TANK-
binding kinase 1 or inducible IκB kinase (32). In addition to 
being activated by TLR-TRIF–dependent pathways (33), 
intracellular receptors such as retinoic acid–inducible gene I 
are capable of activating IRF3 upon recognition of polyI:C 
and RNA viruses (34, 35). After activation, IRF3 promotes 
transcription of type I IFN genes together with other tran-
scription factors, such as NF-κB and activator protein 1 (32, 
36, 37). Although IRF3’s role in type I IFN induction is 
well established, there is emerging data demonstrating that 
IRF3 also functions as a coactivator of NF-κB in the LPS 
response (38, 39). Mechanisms whereby IRF3 might func-
tion to repress target gene expression, however, have not 
been elucidated.
In the analysis of non–type I IFN–related roles of IRF3, 
we have identifi ed a function for this factor in the repres-
sion of nuclear receptor–regulated liver metabolism. In this 
paper, we demonstrate that activation of IRF3 during an 
antiviral immune response profoundly inhibits hepatic ex-
pression of RXRα in vivo. As a consequence of this repres-
sion, the expression of multiple nuclear receptor target genes 
critical for xenobiotic detoxifi cation is compromised. This 
pathway provides a potential molecular mechanism for the 
pathogenesis of Reyes’ syndrome in which acetylsalicylic 
Figure 1. Viral infections negatively regulate in vivo RXR het-
erodimer target genes and liver metabolism. (a and b) Wild-type mice 
(n = 4) were treated with 0.1% NaCl or 2.5 × 107 PFU VSV i.v. on day 1 
with or without vehicle (1% DMSO, maize oil) and 75 mg/kg PCN by ga-
vage for 4 d. Liver RNA was analyzed by Q-PCR. Error bars represent 
mean ± SD. (c) Wild-type mice (n = 4) were treated with 0.1% NaCl or 
2.5 × 107 PFU VSV i.v. on days 1 and 3, as well as vehicle (1% DMSO, 
maize oil) and 75 mg/kg PCN by gavage and/or 0.25 mg/kg LCA i.p. for 4 d. 
Serum was collected and analyzed for serum ALT as described in 
Materials and methods. Error bars represent mean ± SD. *, P ≤ 0.001. 
(d) Representative oil red O staining of livers isolated after treatment 
in c. Bar, 50 μm.
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acid (ASA; i.e., aspirin) treatment during a viral infection 
leads to hepatotoxicity. Repression of RXRα expression 
and downstream target genes by IRF3 may represent a criti-
cal mechanism underlying metabolic diseases associated with 
viral infections.
RESULTS
Antiviral immune response represses RXR𝛂 
and liver metabolism in vivo
To investigate the relationship between liver metabolism 
and viral infections, C57/Bl6 mice were infected with ve-
sicular stomatitis virus (VSV), and nuclear receptor function 
was analyzed. VSV infection potently down-regulated ex-
pression of RXRα mRNA in vivo (Fig. 1 a). Furthermore, 
down-regulation of this critical heterodimeric partner for 
hepatic nuclear receptors was associated with the inhibition 
of multiple nuclear receptor pathways, including induc-
tion of PXR-mediated CYP3A11 by pregnenolone-16α-
 carbonitrile (PCN) and VDR-mediated induction of CYP24 
mRNA by 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3; 
Fig. 1 b and Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20060929/DC1). Furthermore, VSV infec-
tions in the Huh7 hepatocyte cell line resulted in inhibition 
of hepatic LXR, FXR, and PPARα-mediated induction of 
hepatic nuclear receptor target genes (Fig. S1).
Detoxifi cation and clearance of secondary bile acids, such 
as lithocholic acid (LCA), is an important metabolic function 
of the liver required for physiologic homeostasis. Defective 
metabolism of LCA or excessive amounts of LCA results in 
cholestasis and hepatotoxicity. PCN activation of PXR/
RXR has been previously shown to protect the liver from 
secondary bile acid (LCA)–induced hepatotoxicity through 
induction of CYP3A11 and other genes involved in the me-
tabolism of LCA (18, 27). In wild-type mice, administration 
of LCA in excess of natural levels led to signifi cant elevation 
of serum alanine aminotransferase (ALT) levels, which was 
reduced by cotreatment with PCN (Fig. 1 c). To determine 
the impact of viral infection on nuclear receptor–regulated 
bile acid metabolism, the LCA cholestasis model was ana-
lyzed in the context of VSV infection. Although VSV infec-
tion alone had no eff ect on serum ALT levels, it blocked the 
ability of PCN to reduce LCA-induced serum ALT levels 
(Fig. 1 c). Furthermore, VSV infection induced fatty change 
and hepatotoxicity in LCA-treated mice, as demonstrated by 
oil red O staining (Fig. 1 d). The VSV plus LCA-induced 
hepatotoxicity could not be blocked by the addition of PCN. 
Thus, viral infections inhibit PXR/RXR-dependent gene 
expression and promote LCA-induced liver damage.
To determine the mechanism responsible for the inhi-
bition of hepatic gene expression and metabolism observed 
during viral infection, experiments were repeated with polyI:
C, representing viral dsRNA. Treatment with polyI:C re-
sulted in a substantial reduction in RXRα mRNA expression 
(Fig. 2 a). Additionally, polyI:C blunted the induction of 
CYP3A11 by PCN as well as the induction of CYP24 by the 
VDR agonist 1,25(OH)2D3 (Fig. 2 a and Fig. S1). Furthermore, 
hepatic LXR, FXR, and PPARα target genes were also in-
hibited by polyI:C treatment in Huh7 cells (Fig. S1). Both 
polyI:C and viruses such as VSV are known to activate IRF3, 
a key mediator of the antiviral immune response. Experi-
ments with IRF3 knockout mice established that IRF3 was 
critical for the repression of RXRα and hepatic nuclear re-
ceptor target genes by polyI:C (Fig. 2 a and Fig. S1). Further-
more, addition of the nuclear receptor agonist PCN to polyI:
C treatment resulted in a further loss of RXRα protein 
 expression (Fig. 2 b).
Similar to the results obtained with VSV, treatment of 
mice with polyI:C alone did not signifi cantly increase serum 
ALT levels. However, polyI:C in combination with LCA 
strongly induced liver damage, and this damage was not 
blocked by PCN (Fig. 2, c and d). Moreover, polyI:C failed 
to promote LCA-mediated increases of serum ALT levels or 
enhance liver damage in IRF3−/− mice, demonstrating the 
requirement for IRF3 in polyI:C regulation of hepatic gene 
expression and function. (Fig. 2, c and d). These experiments 
establish that viral activation of IRF3 inhibits hepatic nuclear 
receptor target gene induction and metabolic activity, result-
ing in potentiation of LCA-mediated hepatotoxicity.
PolyI:C and LPS repress RXR𝛂 expression through IRF3
To gain a greater understanding of the molecular mechanisms 
behind innate immune system repression of RXRα and 
RXRα target genes, we confi rmed, by quantitative PCR 
(Q-PCR), that polyI:C and LPS repressed RXRα mRNA 
in bone marrow–derived macrophages (BMMs) after 4 h of 
stimulation (Fig. 3 a). Furthermore, an extended time course 
indicated that polyI:C is a more potent repressor of RXRα 
mRNA than LPS (Fig. 3 b). These data validate the in vitro 
model as representative of our in vivo studies, because RXRα 
mRNA expression is inhibited by viral infections and TLR 
ligands in both systems. Protein expression analysis revealed 
that RXRα protein loss after polyI:C treatment was more 
obvious upon the addition of RXR-specifi c (LG268, LG) or 
LXR-specifi c (GW3965, GW3) agonists (Fig. 3 d). Previously, 
IRF3 was found to be involved in the repression of LXR tar-
get genes in BMMs (31). Because RXRα cell type– specifi c 
knockout studies have demonstrated critical roles for RXRα 
target genes (19, 26, 40, 41), we examined the mechanism 
for such repression in greater detail.
Next, we explored the mechanism of RXRα repression 
by analyzing the contribution of IRF3 and type I IFNs, as 
these are the main signaling mediators shared by TLR3 and 
TLR4 but not TLR9 in macrophages. PolyI:C-mediated in-
hibition of RXRα was defective in IRF3−/− BMMs but not 
IFNAR−/− BMMs (Fig. 3 c). Similar regulation was seen at 
the protein level, as RXRα protein expression levels were 
considerably higher in IRF3−/− compared with IFNAR−/− 
BMMs (Fig. 3 e). Although there was some loss of RXRα 
protein in IRF3−/− BMMs after polyI:C and LG268 treat-
ment, the protein levels were substantially higher than in 
wild-type or IFNAR−/− BMMs, whereas upstream stimu-
latory factor 2 (USF2) levels were equivalent. These data 
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suggest the existence of an IRF3-dependent, type I IFN–in-
dependent pathway for RXRα repression.
Optimal transcription of nuclear receptor target genes 
is known to require degradation of nuclear receptors, such 
as RXRα, by the 26S proteosome complex (42). New pro-
tein synthesis replaces degraded nuclear receptors on the 
promoters of these target genes during transcription (42). 
We analyzed whether nuclear receptor activation of the 26S 
proteosome complex would coordinate with IRF3-mediated 
inhibition of RXRα mRNA expression to contribute to the 
loss of RXRα protein. Indeed, MG132, a 26S proteosome 
complex inhibitor, prevented loss of RXRα protein after 
co-stimulation with the RAR/RXR agonist 9-cis retinoic 
acid (9cRA) and polyI:C in BMMs (Fig. 3 f). Thus, maximal 
RXRα protein loss likely requires combinatorial repres-
sion of RXRα mRNA by polyI:C and activation of 26S 
 proteosome complex–mediated degradation by nuclear 
 receptor agonists.
Figure 2. PolyI:C negatively regulated in vivo RXR heterodimer tar-
get genes and liver metabolism. (a) Wild-type or IRF3−/− mice (n = 4) 
were treated with 0.1% NaCl or 150 μg polyI:C i.v. on days 1 and 3 with or 
without vehicle (1% DMSO, maize oil) or 75 mg/kg PCN by gavage for 4 d. 
Liver RNA were analyzed by Q-PCR. Error bars represent represent mean ± 
SD. (b) Representative anti-RXRα and anti-USF2 Western blots of wild-type 
livers after treatment with 0.1% NaCl or 150 μg polyI:C i.v. on days 1 and 3 
with or without vehicle or 75 mg/kg PCN by gavage for 4 d. (c) Wild-type or 
IRF3−/− mice (n = 4) were treated with 0.1% NaCl or 150 μg polyI:C i.v. on 
days 1 and 3, as well as vehicle (1% DMSO, maize oil) and 75 mg/kg PCN by 
gavage and/or 0.25 mg/kg LCA i.p. for 4 d. Serum was collected and ana-
lyzed for serum ALT as described in Materials and methods. Error bars rep-
resent mean ± SD. *, P ≤ 0.001. (d) Representative H&E staining of livers 
isolated after treatment in c. Arrows indicate necrotic foci. Bar, 100 μm.
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IRF3 inhibits RXR𝛂 transcription through induction 
of the transcriptional suppressor Hes1
We further analyzed potential transcriptional and posttran-
scriptional mechanisms through which polyI:C might repress 
RXRα. BMMs were pretreated with or without polyI:C for 
2 h and treated with actinomycin D (a transcription inhib-
itor) to measure RXRα mRNA stability. No important 
 diff erences were observed in RXRα mRNA stability from 
samples treated with or without polyI:C, suggesting that 
 repression is not posttranscriptionally regulated (Fig. 4 a). 
Furthermore, RXRα primary transcripts measured by Q-PCR 
using primers that amplify a region spanning an exon and in-
tron were strongly repressed after polyI:C treatment (Fig. 4 a). 
Collectively, these data indicate that polyI:C regulates RXRα 
expression at the level of transcription.
To gain greater insight into how RXRα is transcription-
ally repressed by polyI:C, the promoter region of RXRα 
(from −1 to −1,000 bp) was analyzed for predicted tran-
scription factor binding sites. Using promoter analysis soft-
ware (see legend to Fig. 4), highly predicted binding sites 
were identifi ed by core similarity (>0.9) and matrix similar-
ity (>0.9). The fi rst 400 bp of the promoter identifi ed multi-
ple hits for three known transcriptional repressors: Hes1, 
ZF5, and ZNF202 (Fig. 4 b). Hes1 and ZNF202 have previ-
ously been identifi ed as potential transcriptional regulators of 
cholesterol metabolism (43, 44). Hes1 mRNA was potently 
induced by polyI:C and LPS (Fig. 4 b), whereas ZF5 and 
ZNF202 mRNA levels were unaff ected (not depicted). Al-
though it is known that NF-κB activators like TNF-α can 
induce Hes1 (45), our data indicate that polyI:C induction of 
Hes1 also involves IRF3 but not type I IFNs (Fig. 4 b). Pre-
liminary Hes1 promoter analysis indicates an IFN-stimulated 
regulatory element (−722/−751) with core similarity of 1 
and matrix similarity of 0.91 (unpublished data), but further 
studies are required to determine if direct binding of IRF3 to 
the Hes1 promoter is involved in the polyI:C-induced Hes1 
up-regulation.
To assess the ability of Hes1 to repress RXRα and RXR-
related genes, RAW 264.7 cells stably transfected with 
pCMV-Hes1 were compared with empty vector controls in 
terms of RXRα mRNA expression and function. Fig. 4 c 
shows that overexpression of Hes1 led to the specifi c down-
regulation of RXRα mRNA, with control L32 mRNA be-
ing unaff ected. Furthermore, knockdown experiments with 
siRNA specifi c to Hes1 demonstrated the requirement of 
Hes1 in polyI:C-mediated repression of RXRα (Fig. 4 d).
Hes1 mediates gene repression by recruiting the Gro/
TLE tetramer and histone deacetylase 1 (HDAC1) complex 
to the promoter region of its target genes (46). Chromatin 
immunoprecipitation of Hes1 and HDAC1 demonstrated 
that polyI:C promotes specifi c recruitment of Hes1 and 
HDAC1 to the RXRα promoter region and predicted Hes1 
binding site (Fig. 4, e and f). To test if recruitment of Hes1 
and HDAC1 is involved in polyI:C repression of RXRα, 
BMMs were pretreated with or without the HDAC1 inhibi-
tor, trichostatin A (TSA), followed by stimulation with polyI:C. 
The addition of TSA prevented polyI:C repression of RXRα 
and allowed polyI:C to induce RXRα (Fig. 4 g), providing 
further evidence for a novel mechanism of repression of 
RXRα by polyI:C.
Transcriptional repression of RXR𝛂 results in defective 
induction of RXR target genes
We predicted that the expression of RXRα target genes 
would mirror regulation of RXRα by polyI:C. Indeed, just 
as polyI:C induced down-regulation of RXRα requires IRF3 
Figure 3. RXR𝛂 repression by polyI:C/LPS requires IRF3 but not 
type 1 IFNs. (a) BMMs were stimulated with 10 ng/ml LPS or 1 μg/ml 
polyI:C for 4 h. RNA was collected and analyzed by Q-PCR. (b) BMMs were 
stimulated with 10 ng/ml LPS or 1 μg/ml polyI:C for 1, 4, or 8 h. RNA was 
analyzed by Q-PCR. (c) Wild-type, IRF3−/−, and IFNAR−/− BMMs and their 
wild-type controls were stimulated with 1 μg/ml polyI:C for 8 h. RNA was 
analyzed by Q-PCR. Error bars in a–c represent mean ± SD. (d) BMMs 
were stimulated with control (DMSO), 10 nM LG268, and 1 μM GW3965 
with or without 1 μg/ml polyI:C for 24 h. Anti-RXRα and anti-USF2 
Western blot analysis was done with 75 μg of whole cell extract. (e) Wild-
type, IRF3−/−, and IFNAR−/− BMMs were stimulated with control (DMSO), 
10 nM LG268, and 1 μg/ml polyI:C for 24 h. Anti-RXRα and anti-USF2 
Western blot analysis was done with 75 μg of whole cell extract. 
(f) BMMs were stimulated with control (DMSO) or 10 μM MG132 with or 
without control (DMSO) or 9cRA and polyI:C. Anti-RXRα and anti-USF2 
Western blot analysis was done with 75 μg of whole cell extract.
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and is independent of type I IFNs, induction of the RXRα 
target gene CRBPII by synthetic RXR ligand (LG268) was 
repressed by polyI:C in IFNAR−/− BMMs but not IRF3−/− 
BMMs (Fig. 5 a). Because repression of RXRα by polyI:C 
appears to require Hes1, we analyzed the role of Hes1 in 
 repression of RXRα target genes. As seen in Fig. 5 b, 
Figure 4. PolyI:C transcriptionally represses RXR𝛂 through recruit-
ment of transcriptional repression machinery. (a) BMMs were stimu-
lated with media or 1 μg/ml polyI:C for 2 h, followed by 5 μg/ml 
actinomycin D (Act D) for 0, 15, 30, 60, and 120 min. BMMs were stimulated 
with 1 μg/ml polyI:C for 4 or 8 h. RNA was analyzed by Q-PCR. (b) Diagram 
of the RXRα promoter based on promoter analysis software (MatInspector; 
www.genomatix.de). BMMs were stimulated with 10 ng/ml LPS or 1 μg/ml 
polyI:C for 4 h. RNA was analyzed by Q-PCR. Wild-type, IRF3−/−, and IF-
NAR−/− BMMs were stimulated with 1 μg/ml polyI:C for 4 h. RNA was ana-
lyzed by Q-PCR. (c) pCMV–RAW 264.7 cells (MT) or pCMV–Hes1–RAW 264.7 
cells (Hes1). RNA was analyzed by Q-PCR. (d) RAW264.7 cells transfected 
with siNS or siHes1 duplex oligos were stimulated with 1 μg/ml polyI:C for 
8 h. RNA was analyzed by Q-PCR. Error bars in a–d represent mean ± SD. 
(e and f) BMMs were stimulated with 1 μg/ml polyI:C for 1, 3, and 6 h. After 
stimulation, chromatin immunoprecipitation was performed with anti-Hes1 
or anti-HDAC1 antibodies on sonicated samples, washed thoroughly, and 
analyzed by PCR/agarose gel electrophoresis. PCR products on gel are quan-
tifi ed by ImageJ, normalized to input. (g) BMMs were pretreated with 50 ng/ml 
TSA overnight and stimulated with 1 μg/ml polyI:C for 4 and 8 h. RNA was 
analyzed by Q-PCR. Error bars represent mean ± SD.
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 overexpression of Hes1 in RAW 264.7 cells prevents the 
RAR/RXR agonist, 9cRA, from inducing CRBPII and 
ABCA1. Furthermore, polyI:C is unable to repress 9cRA in-
duction of CRBPII in cells with knockdown of Hes1 (Fig. 5 c).
To determine if loss of RXRα contributes to polyI:C 
repression of nuclear receptor–regulated genes, we analyzed 
RAW 264.7 cells stably expressing RXRα (Fig. S2, available 
at http://www.jem.org/cgi/content/full/jem.20060929/DC1). 
PolyI:C was unable to repress LG268-induced CRBPII in 
the RXRα-overexpressing RAW 264.7cells (Fig. 5 d). Addi-
tionally, we examined whether repression of RXRα is a key 
requirement of polyI:C repression of RXRα target hepatic 
genes. As seen in Fig. 5 e, transfected polyI:C was capable 
of repressing rifampicin induction of the human homologue 
to CYP3A11, CYP3A4, in Huh7 cells, a human hepatocyte 
cell line. In the presence of RXRα overexpression (Fig. S2), 
however, polyI:C no longer repressed CYP3A4 (Fig. 5 e). 
These results were matched in the induction of another 
RXR-regulated gene, uridine diphosphate glucuronosyltransferase 
1A6 (UGT1A6), which is induced by and metabolizes ASA 
(Fig. 5 f) (47, 48).
Finally, we also confi rmed by chromatin immunoprecipi-
tation that transcriptional repression of RXRα results in a re-
duction of RXRα present on the promoter of RXRα target 
hepatic gene, CYP3A4. As shown in Fig. 5 (g and h), combi-
natorial treatment of Huh7 cells with rifampicin and polyI:C 
resulted in maximal loss of RXRα in the PXR/RXR ER6 
binding region of CYP3A4, whereas binding was minimal 
and unchanged in the upstream coding region. These data 
present evidence that IRF3-mediated transcriptional repres-
sion of RXRα by transfected and nontransfected polyI:C is 
integral to the repression of RXR-related target genes.
Viral infection greatly enhanced ASA hepatotoxicity, 
a potential mouse model of Reye’s syndrome
Based on our in vivo and in vitro results, we hypothesized 
that metabolic disorders involving both nuclear receptor–
regulated xenobiotic metabolism and viral infections might 
involve the repression of RXR target genes by IRF3 during 
host immune response. A human disease that involves viral 
infection and metabolic hepatotoxicity is Reye’s syndrome, 
characteristically presenting with delirium and fatty degener-
ation of the liver in a child with a history of an antecedent viral 
infection treated with ASA. We speculated that the patho-
genesis of Reye’s syndrome might be caused, at least in part, 
by this mechanism of antiviral immune response and nuclear 
receptor cross talk and subsequent metabolic dysfunction. To 
test this hypothesis, we analyzed the eff ects of ASA treatment 
in the presence and absence of an antiviral immune response 
initiated by polyI:C or VSV. Treatment of mice with ASA, 
polyI:C, or VSV alone did not cause substantial hepatotoxicity. 
Administration of ASA to mice treated with polyI:C or 
infected with VSV, however, caused severe hepatotoxicity, 
as indicated by liver necrosis or fatty degeneration (Fig. 6, a 
and d). Consistent with a Reye’s syndrome–like phenotype, 
serum ALT, ammonia, and total bilirubin levels were increased 
during coadministration of ASA and polyI:C or VSV, whereas 
blood glucose levels were signifi cantly decreased (Fig. 6, b, 
c, and e–g) (49–51). Interestingly, hepatotoxicity from expo-
sure to polyI:C plus ASA did not occur in IRF3−/− mice, but 
did occur in IFNAR−/− mice (Fig. 6, d–f). It has been previ-
ously shown that polyI:C treatment results in defective ASA 
metabolism, possibly contributing to the hepatotoxicity seen 
in our experiment (52). In addition to CYP3A4 (53, 54), 
 another enzyme that is induced by ASA and involved in the 
metabolism of ASA is UGT1A6, whose gene is also regulated 
by PXR/RXR (48). UGT1A6 glucoronidates the ASA in-
termediate, salicylic acid (55), and defects in UGT1A6 have 
been associated with impaired metabolism of aspirin (47). In-
terestingly, treatment with ASA or the PXR/RXR agonist 
PCN potently increased UGT1A6 and CYP3A11 mRNA 
in vivo, but not other PXR/RXR genes such as Oatp2 that 
are likely not involved in ASA metabolism (Fig. 1 b; Fig. 2 a; 
Fig. 7, a and b; and Fig. S3, available at http://www.jem.
org/cgi/content/full/jem.20060929/DC1). Furthermore, 
this induction was diminished by either polyI:C stimulation 
or VSV infection (Fig. 1 b; Fig. 2 a; Fig. 7, a and b; and Fig. 
S3). Additionally, the repression of UGT1A6 by polyI:C was 
dependent on IRF3 (Fig. S3). The biological loss of RXRα 
likely contributes to this eff ect. Just as the loss of RXRα de-
creases CYP3A11 expression in mice or CYP3A4 in Huh7 
cells (Fig. 7 e) (23), UGT1A6 induction by ASA is impaired 
in Huh7 cells that have RXRα silenced by siRNA (Fig. 7 e), 
and ASA and polyI:C cotreatment resulted in a considerable 
loss of RXRα protein, just as PCN and polyI:C treatment 
led to the potent loss of RXRα protein (Fig. 7 d).
Mechanisms for ASA toxicity are likely through mem-
brane permeability transition and mitochondrial injury, 
which is caused by ASA’s intermediate, salicylic acid, desta-
bilization of mitochondrial calcium homeostasis (56). Rho-
damine 123 assays demonstrate that RXRα repression by 
polyI:C results in loss of mitochondrial membrane potential 
in mock-transfected Huh7 cells cotreated with ASA and 
polyI:C but not in Huh7 cells overexpressing RXRα 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20060929/DC1). These in vivo and in vitro observa-
tions provide evidence that cross talk between antiviral 
 immune responses and nuclear receptor signaling may play 
a critical role in the pathogenesis of Reye’s syndrome.
D I S C U S S I O N 
The connection between viral infections and metabolic dys-
function is an important clinical problem, yet the mecha-
nisms linking these events are not understood. In this paper 
we provide in vivo evidence for a novel pathway linking viral 
infection to metabolic disease. We have shown that activa-
tion of IRF3 during the viral immune response leads to a 
profound suppression of RXRα mRNA and protein expres-
sion. Because RXRα serves as an obligatory heterodimeric 
partner for several nuclear receptors involved in metabolic 
control, these observations provide a molecular explanation for 
how viral infections can alter a range of metabolic pathways. 
2596 ANTIVIRAL REPRESSION OF RXRα-RELATED GENES AND FUNCTIONS | Chow et al.
Figure 5. PolyI:C transcriptional repression of RXR𝛂 is critical for 
repression of nuclear receptor target genes. (a) Wild-type, IRF3−/−, 
and IFNAR−/− BMMs were stimulated with control (DMSO) or 10 nM 
LG268 with or without 1 μg/ml polyI:C. RNA was analyzed by Q-PCR. 
(b) pCMV–RAW 264.7 cells (MT) or pCMV–Hes1–RAW 264.7 cells (Hes1) 
were stimulated with control (DMSO) and 9cRA with or without 1 μg/ml 
polyI:C for 24 h. RNA was analyzed by Q-PCR. (c) RAW 264.7 cells trans-
fected with siNS or siHes1 duplex oligos were stimulated with control 
(DMSO) and 10 μM 9cRA with or without 1 μg/ml polyI:C for 24 h. 
RNA was analyzed by Q-PCR. (d) pBabe–RAW 264.7 cells (RAW-MT) and 
pBabe-RXRα–RAW264.7 cells (RAW-RXRα) were stimulated with control 
(DMSO) or 10 nM LG268 with or without 1 μg/ml polyI:C for 24 h. 
RNA was analyzed by Q-PCR. (e) pBabe-Huh7 cells (Huh7-MT) and pBabe-
RXRα-Huh7 cells (Huh7-RXRα) were stimulated with control (DMSO) and 
25 μM rifampicin with or without 2 μg/ml polyI:C (transfected). RNA was 
analyzed by Q-PCR. (f) pBabe-Huh7 cells (Huh7-MT) and pBabe-RXRα-
Huh7 cells (Huh7-RXRα) were stimulated with control (DMSO) and 
20 μg/ml ASA with or without 2 μg/ml polyI:C (transfected). RNA was 
analyzed by Q-PCR. Error bars in a–f represent mean ± SD. (g and h) BMMs 
were stimulated with 25 μM rifampicin and 1 μg/ml polyI:C for 24 h. 
After stimulation, chromatin immunoprecipitation was performed with 
anti-RXRα antibody on sonicated samples, washed thoroughly, and ana-
lyzed by PCR/agarose gel electrophoresis. PCR products on gel are quanti-
fi ed by ImageJ, normalized to input. Error bars represent mean ± SD.
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As a consequence of RXRα suppression during viral infec-
tion, the expression of multiple downstream nuclear receptor 
target genes is compromised, including those required for 
liver detoxifi cation of endogenous and exogenous com-
pounds and those required for lipid metabolism. Moreover, 
the ability of viral infections to repress nuclear receptor func-
tion leads to hepatotoxicity in the context of endogenous 
toxins such as LCA and exogenous compounds such as ASA. 
Figure 6. PolyI:C and viral infection promote ASA-related hepato-
toxicity through IRF3, independent of type I IFNs. (a) Representative 
oil red O staining of livers from wild-type mice (n = 4) treated with 0.1% 
NaCl or 2.5 × 107 PFU VSV i.v. on day 1 with or without 3.25 g/L ASA in 
drinking water for 4 d. Bar, 50 μm. (b and c) Wild-type mice (n = 4) were 
treated with 0.1% NaCl or 2.5 × 107 PFU VSV i.v. on day 1 with or without 
325 mg/L ASA in drinking water for 4 d. Serum was collected, and serum 
ALT and blood glucose were analyzed as described in Materials and meth-
ods. Error bars represent mean ± SD. *, P ≤ 0.001. (d) Representative H&E 
staining of livers from wild-type, IRF3−/−, and IFNAR−/− mice treated 
with 0.1% ΝaCl or 150 μg poly I:C i.v. on days 1 and 3 with or without 
3.25 g/L ASA in drinking water for 4 d. Arrows indicate necrotic foci. Bar, 
100 μm. (e and f) Wild-type, IRF3−/−, or IFNAR−/− mice (n = 4) were 
treated with 0.1% NaCl or 150 μg polyI:C i.v. on days 1 and 3 with or 
without 3.25 g/L ASA in drinking water for 4 d. Serum was collected, and 
serum ALT and blood glucose were analyzed as described in Materials and 
methods. Error bars represent mean ± SD. *, P ≤ 0.001. (g) Wild-type 
mice (n = 4) were treated with 0.1% NaCl or 2.5 × 107 PFU VSV i.v. on 
day 1 or 150 μg polyI:C i.v. on days 1 and 3 with or without 3.25 g/L ASA 
in drinking water for 4 d. Serum was collected, and serum ammonia 
and total bilirubin levels were analyzed as described in Materials and 
methods. *, P ≤ 0.01.
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These data provide a molecular mechanism to explain how 
viral infections may interfere with liver homeostasis and con-
tribute to the pathogenesis of metabolic disease (Fig. 8).
The clinical relevance of IRF3-mediated inhibition of 
liver metabolism is illustrated by its potential role in the 
pathogenesis of hepatic metabolic disorders that involve xe-
nobiotics (drugs and chemicals) ingested during viral infec-
tions. One such disorder, Reye’s syndrome, has yet to be 
explained mechanistically. It is known that ASA therapy dur-
ing a viral infection in children can lead to fatty degeneration 
of the liver and encephalopathy (2). Not specifi c to any virus 
in particular, Reye’s syndrome is associated with chickenpox, 
infl uenza A or B, adenoviruses, hepatitis A viruses, para-
myxovirus, picornaviruses, reoviruses, herpesviruses, measles, 
and varicella-zoster viruses (49, 57–62). Previous experiments 
have suggested that hepatotoxicity in Reye’s syndrome re-
sults from a toxic combination of ASA metabolites and in-
fl ammatory cytokines generated in response to a viral infection 
(63). It has also been shown that polyI:C can inhibit the me-
tabolism of aspirin, and this has been suggested to occur 
through type I IFNs (52). Our experimental model of polyI:
C/VSV and ASA treatment, however, clearly demonstrates 
that hepatotoxicity and fatty degeneration occurs in an IRF3-
dependent, type I IFN–independent manner, consistent with 
those seen during Reye’s syndrome. Furthermore, it appears 
that this pathogenesis arises from IRF3 repression of RXRα 
and its hepatic target genes involved in ASA metabolism. We 
showed that this repression of RXRα blocks ASA and PCN 
induction of UGT1A6 and CYP3A11, RXR heterodimer 
target genes involved in ASA metabolism, and results in in-
creased mitochondrial damage by ASA, a known contribut-
ing factor to the pathogenesis of Reye’s syndrome (56, 
64–66). Our results therefore provide compelling evidence 
for the involvement of IRF3–nuclear receptor cross talk in 
the development of Reye’s syndrome and suggest new thera-
peutic strategies for the prevention of hepatotoxicity associ-
ated with viral infections.
Our results also demonstrate that viral infections can alter 
the clearance of endogenous toxins that accumulate during 
normal metabolism. LCA, a secondary bile acid produced by 
intestinal bacteria, is metabolized by RXR heterodimers 
through the induction of cytochrome P450 family members 
such as CYP3A11, which catalyze the initial hydroxylation of 
LCA (67). Mice defi cient in hepatocyte PXR or RXRα ex-
hibit functional defects in the expression of LCA metabolic 
Figure 7. PolyI:C and viral infection inhibit ASA induction of 
UGT1A6. (a) Wild-type mice (n = 4) were treated with 0.1% NaCl or 2.5 × 
107 PFU VSV i.v. on day 1 with or without 3.25 g/L ASA in drinking water 
for 4 d. Liver samples were isolated, and RNA was analyzed by Q-PCR. 
(b) Wild-type mice (n = 4) were treated with 0.1% NaCl or 150 μg polyI:C 
i.v. on days 1 and 3 with or without 3.25 g/L ASA in drinking water for 4 d. 
Liver samples were isolated, and RNA was analyzed by Q-PCR. Error bars 
in a and b represent mean ± SD. (c) Representative Western blot of RXRα 
and USF2 from samples in b. (d and e) Huh7 cells transfected with siNS 
or siRXRα duplex oligos were stimulated with 25 μM rifampicin or 
20 μg/ml ASA for 24 h. RNA was analyzed by Q-PCR. Error bars represent 
mean ± SD.
Figure 8. Model of IRF3 nuclear receptor cross talk and biological 
consequence. Activation of IRF3 through pattern recognition receptors 
(PRRs) results in the induction of antiviral genes through type I IFNs or 
the repression of RXRα target genes through Hes1. The repression of 
RXRα target genes, such as CYPs and UGTs, results in a decrease in RXR-
mediated metabolism and pathogenesis of metabolic disorders such as 
Reye’s syndrome.
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genes (18, 27, 41). Excess amounts of LCA disturb liver ho-
meostasis and result in cholestasis, which can be alleviated by 
the activation of PXR/RXR with less toxic but more potent 
nuclear receptor agonists such as PCN (18, 27). In this work, 
we have shown that activation of IRF3 during viral infection 
inhibits PXR/RXR-dependent activation of CYP3A11. 
Consequently, viral infections render mice highly susceptible 
to LCA-mediated cholestasis and hepatotoxicity. Interest-
ingly, this mechanism may be relevant to viral-induced cho-
lestasis in humans, as Epstein-Barr virus infections have been 
linked to cholestasis (68). The molecular pathways elucidated 
in our study will likely provide a useful framework for further 
investigation into this connection.
IRF3 is a transcription factor best known for its function 
in type I IFN production during the innate immune response 
against viral infections. Our experiments have identifi ed a 
new function for virally activated IRF3, repression of RXRα, 
that is independent of the type I IFN pathway. We have 
shown that activation of IRF3 induces expression of the tran-
scriptional repressor Hes1, which binds directly to the proxi-
mal promoter of RXRα and recruits HDAC1 to repress 
transcription. Nevertheless, RXRα protein levels remain 
relatively stable in the absence of a nuclear receptor–activating 
signal. However, in combination with 26S proteosome com-
plex activation by nuclear agonists (ASA, PCN, LG268, and 
GW3965), this pathway results in a biologically important 
loss of RXRα protein that would not be seen in the absence 
of IRF3 activation, where RXRα protein levels are replen-
ished as new transcript is continually made. Although the re-
pression of other nuclear receptors may contribute to our 
observed phenomenoms, mutation of RXRα in hepatocytes 
results in similar in vivo defects in PXR/RXR target gene 
induction and increased LCA sensitivity, as seen in our ex-
periments with polyI:C and VSV, providing further evidence 
that IRF3-mediated down-regulation of RXRα could con-
tribute substantially to the pathogenesis of hepatic metabolic 
diseases (41). Previous work has shown that nuclear receptor 
activation can inhibit IRF3 target genes (39). It is possible 
that the down- regulation of RXRα may relieve this inhibi-
tory eff ect and allow for optimal induction of IRF3 target 
genes involved in antiviral response. However, it is not clear 
whether this RXRα down-regulation will be benefi cial 
overall or harmful to the host during a microbial infection.
The central role of RXRα in nuclear receptor signaling 
raises the possibility that IRF3–nuclear receptor cross talk 
may have implications for a variety of pathways and meta-
bolic functions. The particular importance of the RXRα iso-
form is clear in that RXRα-defi cient mice are embryonic 
lethal (19, 69). Furthermore, several tissue-specifi c RXRα-
defi cient mice have been described that point to diverse 
functions for this receptor (26, 40, 41). Loss of RXRα has 
been demonstrated in our work and by others to inhibit 
some, but not all, RXR heterodimer target genes, suggesting 
that other factors may play overlapping roles in determining 
activation and maintenance of certain nuclear receptor target 
genes (31, 41). However, it is clear from our work and these 
genetic studies of RXRα that loss of RXRα would aff ect 
several nuclear receptor pathways. Thus, in addition to con-
tributing to the pathogenesis of Reye’s syndrome, IRF3 re-
pression of RXRα may contribute to other diseases associated 
with viral infections. One such disease is atherosclerosis, 
where IRF3 activation contributes to negative regulation of 
LXR-related genes and cholesterol effl  ux (31). It will be in-
teresting to explore whether IRF3-dependent down-regula-
tion of RXRα infl uences disorders such as Gianotti-Crosti 
syndrome in the skin (6, 70) and viral-linked diabetes (5). 
IRF3–nuclear receptor cross talk provides a new understand-
ing of the link between microbial infection and metabolic 
dysfunction and suggests novel targets for therapeutic inter-
vention in these syndromes.
MATERIALS AND METHODS
Cell culture and mice. Mouse BMMs were diff erentiated from marrow as 
described previously (71). IFNAR−/− and IRF3−/− mice (a gift from T. 
Taniguchi, University of Tokyo, Tokyo, Japan) were obtained as previously 
described (71). Cells from F5 C57BL/6 littermate wild-type mice were used 
as wild-type controls for experiments using cells from IFNAR−/− and 
IRF3−/− mice. C57BL/6 mice were used for all experiments not involving 
IFNAR−/− and IRF3−/− mice (obtained from Jackson ImmunoResearch 
Laboratories). RAW 264.7 mouse macrophage cells were cultured in 
DMEM supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. Stable RAW-RXRα or RAW-MT vector cells and Huh7-
RXRα or Huh7-MT vector cells were made by retroviral transduction and 
selected with puromycin. Stable RAW-Hes1 or RAW-MT vector was 
made by transfecting RAW 264.7 cells with 5 μg pCMV-Hes1 or 5 μg 
pCMV and 0.5 μg pBabe-puro with Superfect (QIAGEN) and selected 
with puromycin.
Virus collection and quantifi cation. GFP-tagged VSV was a kind gift 
from G. Barber (University of Miami, Miami, FL). The virus was grown on 
nearly confl uent Madin Darby canine kidney (MDCK) cells, infected at a 
multiplicity of infection of 0.001. 2 d after infection, cell-free supernatant 
was ultracentrifuged at >100,000 g through a 25% sucrose cushion. The 
viral pellet was resuspended in PBS. Standard plaque assay was used to 
 determine the number of PFU. In brief, confl uent monolayers of MDCK 
cells in 6- or 12-well plates were infected in duplicate with serial dilution of 
the viral stock with intermittent shaking for 1 h. Subsequently, cells were 
overlaid with 1× MEM BSA containing 0.7% low-melting-point agar. 
Plaques were allowed to develop over 24–36 h and counted after staining 
cells with crystal violet.
Reagents. Specifi c pattern recognition receptor activation was achieved us-
ing polyI:C for TLR3/retinoic acid–inducible gene I (GE Healthcare) and 
Escherichia coli LPS for TLR4 (Sigma-Aldrich). Synthetic nuclear receptor li-
gands (a gift from T. Willson, GlaxoSmithKline, Research Triangle Park, 
NC) were obtained as previously described (31). LCA, PCN, and ASA were 
obtained from Sigma-Aldrich. 1,25(OH)2D3 was obtained from BIOMOL 
Research Laboratories, Inc. Rifampicin was obtained from Calbiochem. Ac-
tinomycin D and TSA were obtained from Sigma-Aldrich. Macrophage-
CSF–containing media was obtained by growing L929 cells 4 d past 
confl uency and harvesting the conditioned media.
Animal treatments. Age-matched 8–10-wk-old mice were used for all 
experiments. For hepatic nuclear receptor activation and liver functions 
analysis, mice were given vehicle (1% DMSO, maize oil), 75 mg/kg PCN, 
and 7.5 mg/kg 1,25(OH)2D3 by gavage and/or 0.25 mg/kg LCA i.p. for 4 d. 
For polyI:C experiments, mice were also treated with 0.1% NaCl or 150 μg 
polyI:C i.v. on day 1 or 3. For viral infection studies, mice were treated with 
0.1% NaCl or 2.5 × 107 PFU VSV i.v. on day 1. On day 5, mice were 
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killed, and serum and liver samples were collected. ASA treatment was done 
as previously described (72). ASA treatment was done for 3–4 d. Serum ALT 
(TECO Diagnostics), serum ammonia (Pointe Scientifi c), blood glucose 
(LifeScan), and total serum bilirubin (Wako) levels were determined using 
the manufacturers’ protocols. p-values were determined by independent 
t tests compared with controls, unless indicate otherwise in the fi gure legends. 
Animal studies were done in accordance with the Animal Research Com-
mittee of the University of California, Los Angeles.
RNA quantitation. For Q-PCR, total RNA was isolated, and cDNA was 
synthesized as described previously (71). PCR was then performed using 
the thermocycler (iCycler; Bio-Rad Laboratories). Q-PCR was conducted 
in a fi nal volume of 25 μl containing: Taq polymerase, 1× Taq buff er 
(Stratagene), 125 μM deoxyribonucleoside triphosphate, SYBR green I 
(Invitrogen), and fl uoroscein (Bio-Rad Laboratories), using oligo-dT cDNA or 
random hexamer cDNA as the PCR template. Amplifi cation conditions were 
95°C (3 min) and 40 cycles of 95°C (20 s), 55°C (30 s), and 72°C (20 s).
Western blot protein analysis. For Western blots, cell lysates were incu-
bated at room temperature for 5 min with EB lysis buff er (10 mM Tris-HCl 
buff er, pH 7.4, containing 5 mM EDTA, 50 mM NaCl, 0.1% (wt/vol) BSA, 
1% (vol/vol) Triton X-100, and protease inhibitors), size-separated in 10% 
SDS-PAGE, and transferred to nitrocellulose. RXRα and USF2 protein 
levels were detected using rabbit anti-RXRα or anti-USF2 antibody (Santa 
Cruz Biotechnology, Inc.). Whole-cell extract from livers were isolated as 
follows: livers were briefl y homogenized in 1× PBS/protease inhibitors, the 
homogenized product was centrifuged, and the pellet was incubated at room 
temperature for 5 min with EB buff er.
Chromatin immunoprecipitation. CYP3A4 chromatin immunoprecipi-
tation was done as previously described (73). For RXRα chromatin immu-
noprecipitation, inactivated and activated cells were fi xed at room 
temperature for 10 min by adding formaldehyde directly to the culture me-
dium to a fi nal concentration of 1%. The reaction was stopped by adding 
glycine at a fi nal concentration of 0.125 M for 5 min at room temperature. 
After three ice-cold PBS washes, the cells were collected and lysed for 10 
min on ice in cell lysis buff er (5 mM PIPES [piperazine-N,N′-bis(2-ethane-
sulfonic acid)], pH 8, 85 mM KCl, 0.5% NP-40, and protease inhibitors). 
The nuclei were resuspended in nuclei lysis buff er (50 mM Tris-HCl, pH 
8.1, 10 mM EDTA, 1% SDS, and protease inhibitors) and incubated on ice 
for 10 min. Chromatin was sheared into 500- to 1,000-bp fragments by son-
ication and was precleared with protein A or protein G–Sepharose beads. 
The purifi ed chromatin was diluted with chromatin immunoprecipitation 
dilution buff er (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCl, pH 8.1, 167 mM NaCl, and protease inhibitors) and immunopre-
cipitated overnight at 4°C using 2–4 μg of anti-Hes1 (Santa Cruz Biotech-
nology, Inc.) or anti-HDAC1 (Upstate Biotechnology). Immune complexes 
were collected with protein G–Sepharose beads, washed thoroughly, and 
eluted. After protein-DNA cross-linking was reversed and the DNA was 
purifi ed, the presence of selected DNA sequences was assessed by PCR. 
PCR products were analyzed on a 2% agarose gel and quantifi ed with Im-
ageJ (W.S. Rasband, National Institutes of Health, Bethesda, MD; http://
rsb.info.nih.gov/ij/index.html).
siRNA assays. Targeted sequences for the Hes1 siRNA duplex or nonspe-
cifi c siRNA duplex were synthesized by Invitrogen. Duplex oligonucle-
otides were transfected using Lipofectamine (Invitrogen) at a ratio of 10–20 
pmol of RNA to 1.5 μl of Lipofectamine in serum-free, antibiotic-free me-
dia. Media was changed after 4–6 h, and experiments were done 36 h after 
transfection. The target sequence for the Hes1 siRNA was 5′-C G A C A C C-
G G A C A A A C C A A A -3′ (74). The target sequence for the RXRα siRNA 
was 5′-A A G C A C U A U G G A G U G U A C A G C -3′ (75).
Histology. For hematoxylin and eosin (H&E) staining, liver samples were 
fi xed in formalin for 48 h. H&E stainings were done by the University of 
California, Los Angeles Tissue Procurement Core Laboratory (TPCL). For 
oil red O staining, liver samples were snap frozen in OCT compound 
(Sakura Finetek), and frozen tissue sections were made by TPCL. Oil red O 
staining was done in accordance with manufacturer’s protocol (Diagnostic 
BioSystems). In brief, slides were placed in propylene glycol for 2 min, fol-
lowed by oil red O staining for 6 min at 60°C. Slides were washed, and tissue 
was diff erentiated in 85% propylene glycol for 1 min, followed by modifi ed 
Mayer’s hematoxylin staining for 1 min. Slides were again extensively 
washed, and a coverslip was added with an aqueous mounting medium.
Online supplemental material. Fig. S1 shows repression of hepatic nu-
clear receptor target genes by polyI:C/VSV. Fig. S2 shows RXRα expres-
sion levels by Western blot in RXRα-expressing cell lines, compared with 
their controls. Fig. S3 depicts polyI:C repression of PCN-induced UGT1A6 
mRNA and ASA induction of PXR/RXR target genes. Fig. S4 depicts 
polyI:C potentiation of ASA-induced mitochondrial damage. Figs. S1–S4 
are available at http://www.jem.org/cgi/content/full/jem.20060929/DC1. 
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